Annual report pursuant to Section 13 and 15(d)

Note 18 - Segments - Segment Information (Details)

v3.19.1
Note 18 - Segments - Segment Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Revenue from contract with customer $ 338,000  
Grant and other revenue 846,830 $ 1,701,311
Revenue 1,169,351 1,810,437
Cost of revenue 96,636 3,651
Research and development expenses 4,221,881 4,513,842
Selling, general and administrative expenses, excluding depreciation and amortization [1] 7,547,750 10,929,785
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 150,385 240,166
Loss from operations [3] (10,847,301) (13,877,007)
Other income (expense) [4] (5,321,270) (3,912,679)
Benefit from income taxes 9,753 4,062,489
Loss from continuing operations (16,158,818) (13,727,197)
Income from discontinued operations, net of tax effect 1,449 88,673,053
Gain on sale of discontinued operations, net of tax effect 43,053 89,163,811
Net income (loss) (16,114,316) 74,945,856
Total assets, net of depreciation and amortization 7,021,527 20,781,436
Capital expenditures 46,192 33,690
Other income (expense) [4] (5,321,270) (3,912,679)
Benefit from income taxes 9,753 4,062,489
Net income (loss) (16,114,316) 74,945,856
UNITED STATES    
Total assets, net of depreciation and amortization 6,994,317 20,749,109
Non-US [Member]    
Total assets, net of depreciation and amortization 14,711 32,327
Royalty [Member]    
Revenue from contract with customer 15,347 9,126
License [Member]    
Revenue from contract with customer 307,174 100,000
Diagnostics Segment [Member]    
Grant and other revenue 494,997 1,506,232
Revenue 817,518 1,615,358
Cost of revenue 96,636 3,651
Research and development expenses 3,064,115 3,784,255
Selling, general and administrative expenses, excluding depreciation and amortization [1]
Depreciation, Depletion and Amortization, Nonproduction, Total [2]
Loss from operations [3] (2,343,233) (2,172,548)
Other income (expense) [4]
Benefit from income taxes 1,413 496,127
Loss from continuing operations (2,341,820) (1,676,421)
Income from discontinued operations, net of tax effect 1,449 88,673,053
Gain on sale of discontinued operations, net of tax effect 43,053  
Net income (loss) (2,297,318) 86,996,632
Capital expenditures
Other income (expense) [4]
Benefit from income taxes 1,413 496,127
Net income (loss) (2,297,318) 86,996,632
Diagnostics Segment [Member] | UNITED STATES    
Total assets, net of depreciation and amortization 91,425 13,065,871
Diagnostics Segment [Member] | Non-US [Member]    
Total assets, net of depreciation and amortization 14,330 30,476
Diagnostics Segment [Member] | Royalty [Member]    
Revenue from contract with customer 15,347 9,126
Diagnostics Segment [Member] | License [Member]    
Revenue from contract with customer 307,174 100,000
Therapeutics Segment [Member]    
Grant and other revenue 351,833 195,079
Revenue 351,833 195,079
Cost of revenue
Research and development expenses 1,157,766 729,587
Selling, general and administrative expenses, excluding depreciation and amortization [1] 78,606 34,484
Depreciation, Depletion and Amortization, Nonproduction, Total [2]
Loss from operations [3] (884,539) (568,992)
Other income (expense) [4]
Benefit from income taxes 534 129,936
Loss from continuing operations (884,005) (439,056)
Income from discontinued operations, net of tax effect
Gain on sale of discontinued operations, net of tax effect  
Net income (loss) (884,005) (439,056)
Capital expenditures
Other income (expense) [4]
Benefit from income taxes 534 129,936
Net income (loss) (884,005) (439,056)
Therapeutics Segment [Member] | UNITED STATES    
Total assets, net of depreciation and amortization 24,763 49,001
Therapeutics Segment [Member] | Non-US [Member]    
Total assets, net of depreciation and amortization
Therapeutics Segment [Member] | Royalty [Member]    
Revenue from contract with customer
Therapeutics Segment [Member] | License [Member]    
Revenue from contract with customer
Corporate Segment [Member]    
Grant and other revenue
Revenue
Cost of revenue
Research and development expenses
Selling, general and administrative expenses, excluding depreciation and amortization [1] 7,469,144 10,895,301
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 150,385 240,166
Loss from operations [3] (7,619,529) (11,135,467)
Other income (expense) [4] (5,321,270) (3,912,679)
Benefit from income taxes 7,806 3,436,426
Loss from continuing operations (12,932,993) (11,611,720)
Income from discontinued operations, net of tax effect
Gain on sale of discontinued operations, net of tax effect  
Net income (loss) (12,932,993) (11,611,720)
Capital expenditures 46,192 33,690
Other income (expense) [4] (5,321,270) (3,912,679)
Benefit from income taxes 7,806 3,436,426
Net income (loss) (12,932,993) (11,611,720)
Corporate Segment [Member] | UNITED STATES    
Total assets, net of depreciation and amortization 6,878,129 7,634,237
Corporate Segment [Member] | Non-US [Member]    
Total assets, net of depreciation and amortization 381 1,851
Corporate Segment [Member] | Royalty [Member]    
Revenue from contract with customer
Corporate Segment [Member] | License [Member]    
Revenue from contract with customer
[1] General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments. Marketing and selling expenses are allocated to our individual reportable segments.
[2] Depreciation and amortization is reflected in selling, general and administrative expenses ($150,385 and $240,166 for the years ended December 31, 2018 and 2017, respectively).
[3] Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments.
[4] Amounts consist primarily of interest income, interest expense, changes in fair value of financial instruments, and losses on debt extinguishment, which are not currently allocated to our individual reportable segments.